James Marken - ANI Pharmaceuticals Senior Development
| ANIP Stock | USD 64.35 0.52 0.80% |
Executive
Mr. James G. Marken is Senior Vice President, Operations and Product Development of the Company, since may 2016. He had served as ANIPs Vice President, Operations and Product Development, since March 2009. He has served as the Companys Vice President, Operations, since June 2013 and was promoted to Senior Vice President, Operations and Product Development in May 2016. Mr. Marken joined ANIP in March 2007 as General Manager of the Minnesota facilities. As Senior Vice President, Operations and Product Development, Mr. Marken was principally responsible for the following areas manufacturing, packaging, engineeringmaintenance, purchasing, warehousing and product development. Mr. Marken brings over 30 years of pharmaceutical industry experience to the Company. Prior to joining ANIP in March 2007, he worked for Solvay Pharmaceuticals as plant manager and in various departments including quality control, validation and manufacturing since 2016.
| Age | 61 |
| Tenure | 9 years |
| Phone | 218 634 3500 |
| Web | https://www.anipharmaceuticals.com |
James Marken Latest Insider Activity
Tracking and analyzing the buying and selling activities of James Marken against ANI Pharmaceuticals stock is an integral part of due diligence when investing in ANI Pharmaceuticals. James Marken insider activity provides valuable insight into whether ANI Pharmaceuticals is net buyers or sellers over its current business cycle. Note, ANI Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell ANI Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
James Marken over six months ago Disposition of 7250 shares by James Marken of ANI Pharmaceuticals at 49.51 subject to Rule 16b-3 | ||
James Marken over six months ago Disposition of 5300 shares by James Marken of ANI Pharmaceuticals at 57.06 subject to Rule 16b-3 | ||
James Marken over six months ago Disposition of 3653 shares by James Marken of ANI Pharmaceuticals at 69.58 subject to Rule 16b-3 |
ANI Pharmaceuticals Management Efficiency
ANI Pharmaceuticals' management efficiency ratios could be used to measure how well ANI Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Peter Norman | Alkermes Plc | N/A | |
| Samuel Parisi | Alkermes Plc | 50 | |
| Christopher OBrien | Neurocrine Biosciences | 67 | |
| Jane Sorensen | Neurocrine Biosciences | N/A | |
| Bart Dunn | Collegium Pharmaceutical | N/A | |
| Ingrid Delaet | Neurocrine Biosciences | 58 | |
| Darin Esq | Neurocrine Biosciences | 59 | |
| Declan OConnor | Alkermes Plc | N/A | |
| Craig MD | Alkermes Plc | 56 | |
| Eric Benevich | Neurocrine Biosciences | 60 | |
| Shawn Cross | Pacira BioSciences, | 57 | |
| Jose Vieira | Procaps Group SA | 58 | |
| Mike Nanfito | Ironwood Pharmaceuticals | N/A | |
| MD FAAFP | Collegium Pharmaceutical | 63 | |
| Tammi Gaskins | Ironwood Pharmaceuticals | N/A | |
| Kristen JD | Pacira BioSciences, | 51 | |
| Carlos Russo | Procaps Group SA | 39 | |
| Sandra Coombs | Alkermes Plc | N/A | |
| Darin Lippoldt | Neurocrine Biosciences | 58 | |
| Max Reinhardt | Pacira BioSciences, | 53 | |
| Charles Laranjeira | Pacira BioSciences, | 58 | |
Management Performance
| Return On Equity | -0.0418 | ||||
| Return On Asset | 0.0084 |
ANI Pharmaceuticals Leadership Team
Elected by the shareholders, the ANI Pharmaceuticals' board of directors comprises two types of representatives: ANI Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ANI. The board's role is to monitor ANI Pharmaceuticals' management team and ensure that shareholders' interests are well served. ANI Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ANI Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Elizabeth JD, Chief Disease | ||
| Stephen Carey, CFO, Vice President | ||
| Krista Davis, Senior Officer | ||
| Muthusamy RPh, COO RD | ||
| Thomas Rowland, Senior Brands | ||
| Nikhil Lalwani, CEO President | ||
| Meredith Cook, General VP | ||
| Chad Gassert, Senior Strategy | ||
| James Marken, Senior Development | ||
| Ori Gutwerg, Senior Generics | ||
| Meredith JD, General VP | ||
| Christopher Mutz, Senior Disease | ||
| Mary MD, Chief Officer |
ANI Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ANI Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0418 | ||||
| Return On Asset | 0.0084 | ||||
| Profit Margin | (0.03) % | ||||
| Operating Margin | 0.01 % | ||||
| Current Valuation | 1.9 B | ||||
| Shares Outstanding | 21.76 M | ||||
| Shares Owned By Insiders | 11.22 % | ||||
| Shares Owned By Institutions | 97.41 % | ||||
| Number Of Shares Shorted | 2.56 M | ||||
| Price To Earning | 43.35 X |
Additional Tools for ANI Stock Analysis
When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.